Form 4: Aclaris CBO Granted Significant Equity Awards

Aclaris Therapeutics' Chief Business Officer, James Loerop, was granted 97,700 Restricted Stock Units and 341,900 Employee Stock Options.

Summary

• James Loerop, Chief Business Officer of Aclaris Therapeutics, Inc. (ACRS), was granted equity awards on February 2, 2026.
• The grants include 97,700 Restricted Stock Units (RSUs), each representing a contingent right to receive one share of common stock.
• The RSUs will vest in four equal annual installments on the first, second, third, and fourth anniversaries of February 2, 2026, contingent on continuous service.
• Additionally, Mr. Loerop was granted 341,900 Employee Stock Options with an exercise price of $3.61 per share.
• These stock options will become exercisable with respect to 25% of the shares vesting in four equal annual installments on the first, second, third, and fourth anniversaries of February 2, 2026, also contingent on continuous service.
• The Employee Stock Options have an expiration date of February 1, 2036.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, primarily due to the strong alignment of executive incentives with shareholder interests and the retention aspect of the vesting schedule. It is a routine compensation event rather than a direct indicator of operational performance.

Positives

• The equity grants align the Chief Business Officer's interests with those of shareholders, incentivizing long-term performance.
• The vesting schedule, tied to continuous service over four years, acts as a strong retention mechanism for a key executive.

Negatives

• The future issuance of shares upon vesting of RSUs and exercise of options will result in a degree of dilution for existing shareholders.

Future Outlook

The filing indicates a long-term commitment from the Chief Business Officer through equity awards that vest over four years, aligning his future compensation with the company's stock performance.

Industry Context

StockSavvy.ai notes that granting equity awards such as Restricted Stock Units and stock options is a standard practice in the biotechnology and pharmaceutical industries. This compensation structure is widely used to attract, retain, and motivate key executives by linking their personal wealth directly to the company's long-term success and shareholder value creation.

Comparison to Industry Standards

• Equity compensation, including RSUs and stock options, is a common component of executive compensation packages across the biotech sector, comparable to practices at companies like Biogen or Gilead Sciences.
• The four-year vesting schedule is typical for executive equity grants, designed to ensure long-term commitment and performance, aligning with industry benchmarks for executive retention.

Stakeholder Impact

• Shareholders: Potential future dilution from the vesting and exercise of equity awards, but also benefit from enhanced executive alignment with long-term company performance.
• Employees (specifically James Loerop): Receives significant equity compensation, incentivizing continued service and performance.

Next Steps

• The Restricted Stock Units and Employee Stock Options will vest in four equal annual installments on the anniversaries of February 2, 2026, subject to continuous service.

Key Dates

Keywords

Aclaris Therapeutics, ACRS, Form 4, Insider Transaction, Equity Compensation, Restricted Stock Units, Stock Options, James Loerop, Chief Business Officer